e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Diffuse pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The immunomodulatory effect of protein S in pulmonary fibrosis
T. Takagi, M. Urawa, A. Tomaru, K. Fujiwara, M. Onishi, T. Kobayashi, H. Kobayashi, M. Toda, C. D'Alessandro-Gabazza, E. Gabazza, O. Taguchi (Tsu, Japan)
Source:
Annual Congress 2013 –Diffuse pulmonary fibrosis
Session:
Diffuse pulmonary fibrosis
Session type:
Thematic Poster Session
Number:
2323
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Takagi, M. Urawa, A. Tomaru, K. Fujiwara, M. Onishi, T. Kobayashi, H. Kobayashi, M. Toda, C. D'Alessandro-Gabazza, E. Gabazza, O. Taguchi (Tsu, Japan). The immunomodulatory effect of protein S in pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 2323
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Changes in the small airways in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept